2023

Shamis, S. A. K., Savioli, F., Ammar, A. , Al-Badran, S. S.F., Hatthakarnkul, P. , Leslie, H. , Mallon, E., Jamieson, N. B. , McMillan, D. C. and Edwards, J. (2023) Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay. Histology and Histopathology: Cellular and Molecular Biology, (doi: 10.14670/HH-18-655) (Early Online Publication)

Pennel, K., Morrow, E., Hatthakarnkul, P. , Leslie, H. , Mallon, E., Andersen, D., Jamieson, N. , McMillan, D. , Roseweir, A. and Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12(12), pp. 13225-13240. (doi: 10.1002/cam4.6014) (PMID:37199043) (PMCID:PMC10315752)

2022

Shamis, S. A.K., Quinn, J. , Mallon, E. E.A., Edwards, J. and McMillan, D. C. (2022) The relationship between the tumor cell expression of hypoxic markers and survival in patients with ER-positive invasive ductal breast cancer. Journal of Histochemistry and Cytochemistry, 70(7), pp. 479-494. (doi: 10.1369/00221554221110280) (PMID:35792080)

2020

Smith, I. et al. (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, 21(11), pp. 1443-1454. (doi: 10.1016/S1470-2045(20)30458-7) (PMID:33152284) (PMCID:PMC7606901)

2018

Morrow, E., Lannigan, A., Doughty, J., Litherland, J., Mansell, J., Stallard, S., Mallon, E. and Romics, L. (2018) Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. British Journal of Surgery, 105(8), pp. 987-995. (doi: 10.1002/bjs.10791) (PMID:29623677)

Roseweir, A. K. et al. (2018) Predictive biomarkers for endocrine therapy: retrospective study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Journal of the National Cancer Institute, 110(6), pp. 616-627. (doi: 10.1093/jnci/djx255) (PMID:29917140)

Sestak, I. et al. (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncology, 4(4), pp. 545-553. (doi: 10.1001/jamaoncol.2017.5524) (PMID:29450494)

2017

Roseweir, A. K. , McCall, P., Scott, A., Liew, B., Lim, Z., Mallon, E. A. and Edwards, J. (2017) Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 8(23), pp. 37172-37185. (doi: 10.18632/oncotarget.16420) (PMID:28415597) (PMCID:PMC5514900)

Bennett, L., Mallon, E. A., Horgan, P. G. , Paul, A., McMillan, D. C. and Edwards, J. (2017) The relationship between members of the canonical NF-KB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 8(20), pp. 33002-33013. (doi: 10.18632/oncotarget.16031) (PMID:28423692)

Bennett, L., Quinn, J. , McCall, P., Mallon, E. A., Horgan, P. G. , McMillan, D. C. , Paul, A. and Edwards, J. (2017) High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. International Journal of Cancer, 140(7), pp. 1633-1644. (doi: 10.1002/ijc.30578) (PMID:28006839)

Mansell, J., Weiler-Mithoff, E., Stallard, S., Doughty, J.C., Mallon, E. and Romics, L. (2017) Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast, 32, pp. 179-185. (doi: 10.1016/j.breast.2017.02.006) (PMID:28214785)

2016

Campbell, E. J., Tesson, M., Doogan, F., Mohammed, Z. M.A., Mallon, E. and Edwards, J. (2016) The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 115(8), pp. 967-973. (doi: 10.1038/bjc.2016.206) (PMID:27657341)

Kabir, S., Stallard, S., Weiler-Mithoff, E.-M., Mansell, J., Mallon, E., Doughty, J. and Romics, L. (2016) Six-year follow-up of patients treated with oncoplastic reduction mammoplasty: a cohort study. International Journal of Surgery, 26, pp. 38-42. (doi: 10.1016/j.ijsu.2016.01.001) (PMID:26763347)

2015

Metzger Filho, O. et al. (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 33(25), pp. 2772-2779. (doi: 10.1200/jco.2015.60.8133) (PMID:26215945)

Dowsett, M., Sestak, I., Buus, R., Lopez-Knowles, E., Mallon, E., Howell, A., Forbes, J.F., Buzdar, A. and Cuzick, J. (2015) Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer. Clinical Cancer Research, 21(12), pp. 2763-2770. (doi: 10.1158/1078-0432.CCR-14-2842) (PMID:26078431)

2014

Palmieri, C. et al. (2014) NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Research and Treatment, 148(3), pp. 581-590. (doi: 10.1007/s10549-014-3183-4)

Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C. , Morris, J. S. , Cameron, E. R. , Edwards, J. and Blyth, K. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9(6), e100759. (doi: 10.1371/journal.pone.0100759) (PMID:24967588) (PMCID:PMC4072705)

McGlynn, L.M. et al. (2014) SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? European Journal of Cancer, 50(2), pp. 290-301. (doi: 10.1016/j.ejca.2013.10.005) (PMID:24183459)

2013

Mohammed, Z.M.A., Orange, C., McMillan, D.C. , Mallon, E., Doughty, J.C., Edwards, J. and Going, J.J. (2013) Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. Human Pathology, 44(8), pp. 1688-1695. (doi: 10.1016/j.humpath.2012.11.023)

Blamey, R.W. et al. (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. European Journal of Cancer, 49(10), pp. 2294-2302. (doi: 10.1016/j.ejca.2013.02.031)

Bartlett, J.M.S. et al. (2013) Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Research and Treatment, 138(3), pp. 773-781. (doi: 10.1007/s10549-013-2489-y)

Ohotski, J., Edwards, J. , Elsberger, B., Watson, C., Orange, C., Mallon, E., Pyne, S. and Pyne, N.J. (2013) Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. International Journal of Cancer, 132(3), pp. 605-616. (doi: 10.1002/ijc.27692)

2012

Mohammed, Z.M.A., Going, J.J., McMillan, D.C. , Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology, 61(4), pp. 675-684. (doi: 10.1111/j.1365-2559.2012.04280.x)

Mohammed, Z.M.A., Edwards, J. , Orange, C., Mallon, E., Doughty, J., McMillan, D.C. and Going, J.J. (2012) Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology, 61(2), pp. 283-292. (doi: 10.1111/j.1365-2559.2012.04244.x)

Spears, M. et al. (2012) Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 227(4), pp. 481-489. (doi: 10.1002/path.4022)

Mohammed, Z.M.A., McMillan, D.C. , Elsberger, B., Going, J.J., Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 106(2), pp. 383-388. (doi: 10.1038/bjc.2011.569)

Spears, M., Taylor, K.J., Munro, A.F., Cunningham, C.A., Mallon, E.A., Twelves, C.J., Cameron, D.A., Thomas, J. and Bartlett, J.M.S. (2012) In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment, 132(2), pp. 463-470. (doi: 10.1007/s10549-011-1606-z)

2011

Bartlett, J. M. S. et al. (2011) Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 29(12), pp. 1531-1538. (doi: 10.1200/JCO.2010.30.3677)

Cuzick, J. et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. Journal of Clinical Oncology, 29(32), pp. 4273-4278. (doi: 10.1200/JCO.2010.31.2835)

Dowsett, M., Salter, J., Zabaglo, L., Mallon, E., Howell, A., Buzdar, A. U., Forbes, J., Pineda, S. and Cuzick, J. (2011) Predictive algorithms for adjuvant therapy: TransATAC. Steroids, 76(8), pp. 777-780. (doi: 10.1016/j.steroids.2011.02.032)

2009

Tovey, S.M., Brown, S.B., Doughty, J.C., Mallon, E.A., Cooke, T.G. and Edwards, J. (2009) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. British Journal of Cancer, 100(5), pp. 680-683. (doi: 10.1038/sj.bjc.6604940)

2008

Bartlett, J., Campbell, F. and Mallon, E. (2008) Determination of HER2 Amplification by In Situ Hybridization: When Should Chromosome 17 also be Determined? American Journal of Clinical Pathology, 130(6), pp. 920-926.

Bartlett, J. et al. (2008) In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement - In reply. Journal of Clinical Oncology, 26(10), pp. 1769-1771.

Dowsett, M. et al. (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. Journal of Clinical Oncology, 26(7), pp. 1059-1065.

Pestalozzi, B. et al. (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology, 26(18), pp. 3006-3014. (doi: 10.1200/JCO.2007.14.9336)

2005

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. , Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi: 10.1158/1078-0432.CCR-05-0283)

Stein, T. et al. (2005) Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clinical Cancer Research, 11(19), pp. 6872-6879. (doi: 10.1158/1078-0432.CCR-05-0547)

2003

Bartlett, J.M.S., Mallon, E. and Cooke, T. (2003) The clinical evaluation of HER-2 status: which test to use? Journal of Pathology, 199(4), pp. 411-417. (doi: 10.1002/path.1354)

Dowsett, M. et al. (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. Journal of Pathology, 199(4), pp. 418-423. (doi: 10.1002/path.1313)

2002

McIlhenny, C., Doughty, J.C., George, W.D. and Mallon, E.A. (2002) Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. British Journal of Surgery, 89, pp. 84-85.

Thomson, C.S., Twelves, C.J., Mallon, E.A. and Leake, R.E. (2002) Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast, 11, pp. 419-429. (doi: 10.1054/brst.2002.0451)

Articles

Shamis, S. A. K., Savioli, F., Ammar, A. , Al-Badran, S. S.F., Hatthakarnkul, P. , Leslie, H. , Mallon, E., Jamieson, N. B. , McMillan, D. C. and Edwards, J. (2023) Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay. Histology and Histopathology: Cellular and Molecular Biology, (doi: 10.14670/HH-18-655) (Early Online Publication)

Pennel, K., Morrow, E., Hatthakarnkul, P. , Leslie, H. , Mallon, E., Andersen, D., Jamieson, N. , McMillan, D. , Roseweir, A. and Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12(12), pp. 13225-13240. (doi: 10.1002/cam4.6014) (PMID:37199043) (PMCID:PMC10315752)

Shamis, S. A.K., Quinn, J. , Mallon, E. E.A., Edwards, J. and McMillan, D. C. (2022) The relationship between the tumor cell expression of hypoxic markers and survival in patients with ER-positive invasive ductal breast cancer. Journal of Histochemistry and Cytochemistry, 70(7), pp. 479-494. (doi: 10.1369/00221554221110280) (PMID:35792080)

Smith, I. et al. (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, 21(11), pp. 1443-1454. (doi: 10.1016/S1470-2045(20)30458-7) (PMID:33152284) (PMCID:PMC7606901)

Morrow, E., Lannigan, A., Doughty, J., Litherland, J., Mansell, J., Stallard, S., Mallon, E. and Romics, L. (2018) Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. British Journal of Surgery, 105(8), pp. 987-995. (doi: 10.1002/bjs.10791) (PMID:29623677)

Roseweir, A. K. et al. (2018) Predictive biomarkers for endocrine therapy: retrospective study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Journal of the National Cancer Institute, 110(6), pp. 616-627. (doi: 10.1093/jnci/djx255) (PMID:29917140)

Sestak, I. et al. (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncology, 4(4), pp. 545-553. (doi: 10.1001/jamaoncol.2017.5524) (PMID:29450494)

Roseweir, A. K. , McCall, P., Scott, A., Liew, B., Lim, Z., Mallon, E. A. and Edwards, J. (2017) Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 8(23), pp. 37172-37185. (doi: 10.18632/oncotarget.16420) (PMID:28415597) (PMCID:PMC5514900)

Bennett, L., Mallon, E. A., Horgan, P. G. , Paul, A., McMillan, D. C. and Edwards, J. (2017) The relationship between members of the canonical NF-KB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 8(20), pp. 33002-33013. (doi: 10.18632/oncotarget.16031) (PMID:28423692)

Bennett, L., Quinn, J. , McCall, P., Mallon, E. A., Horgan, P. G. , McMillan, D. C. , Paul, A. and Edwards, J. (2017) High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. International Journal of Cancer, 140(7), pp. 1633-1644. (doi: 10.1002/ijc.30578) (PMID:28006839)

Mansell, J., Weiler-Mithoff, E., Stallard, S., Doughty, J.C., Mallon, E. and Romics, L. (2017) Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast, 32, pp. 179-185. (doi: 10.1016/j.breast.2017.02.006) (PMID:28214785)

Campbell, E. J., Tesson, M., Doogan, F., Mohammed, Z. M.A., Mallon, E. and Edwards, J. (2016) The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 115(8), pp. 967-973. (doi: 10.1038/bjc.2016.206) (PMID:27657341)

Kabir, S., Stallard, S., Weiler-Mithoff, E.-M., Mansell, J., Mallon, E., Doughty, J. and Romics, L. (2016) Six-year follow-up of patients treated with oncoplastic reduction mammoplasty: a cohort study. International Journal of Surgery, 26, pp. 38-42. (doi: 10.1016/j.ijsu.2016.01.001) (PMID:26763347)

Metzger Filho, O. et al. (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 33(25), pp. 2772-2779. (doi: 10.1200/jco.2015.60.8133) (PMID:26215945)

Dowsett, M., Sestak, I., Buus, R., Lopez-Knowles, E., Mallon, E., Howell, A., Forbes, J.F., Buzdar, A. and Cuzick, J. (2015) Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer. Clinical Cancer Research, 21(12), pp. 2763-2770. (doi: 10.1158/1078-0432.CCR-14-2842) (PMID:26078431)

Palmieri, C. et al. (2014) NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Research and Treatment, 148(3), pp. 581-590. (doi: 10.1007/s10549-014-3183-4)

Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C. , Morris, J. S. , Cameron, E. R. , Edwards, J. and Blyth, K. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9(6), e100759. (doi: 10.1371/journal.pone.0100759) (PMID:24967588) (PMCID:PMC4072705)

McGlynn, L.M. et al. (2014) SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? European Journal of Cancer, 50(2), pp. 290-301. (doi: 10.1016/j.ejca.2013.10.005) (PMID:24183459)

Mohammed, Z.M.A., Orange, C., McMillan, D.C. , Mallon, E., Doughty, J.C., Edwards, J. and Going, J.J. (2013) Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. Human Pathology, 44(8), pp. 1688-1695. (doi: 10.1016/j.humpath.2012.11.023)

Blamey, R.W. et al. (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. European Journal of Cancer, 49(10), pp. 2294-2302. (doi: 10.1016/j.ejca.2013.02.031)

Bartlett, J.M.S. et al. (2013) Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Research and Treatment, 138(3), pp. 773-781. (doi: 10.1007/s10549-013-2489-y)

Ohotski, J., Edwards, J. , Elsberger, B., Watson, C., Orange, C., Mallon, E., Pyne, S. and Pyne, N.J. (2013) Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. International Journal of Cancer, 132(3), pp. 605-616. (doi: 10.1002/ijc.27692)

Mohammed, Z.M.A., Going, J.J., McMillan, D.C. , Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology, 61(4), pp. 675-684. (doi: 10.1111/j.1365-2559.2012.04280.x)

Mohammed, Z.M.A., Edwards, J. , Orange, C., Mallon, E., Doughty, J., McMillan, D.C. and Going, J.J. (2012) Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology, 61(2), pp. 283-292. (doi: 10.1111/j.1365-2559.2012.04244.x)

Spears, M. et al. (2012) Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 227(4), pp. 481-489. (doi: 10.1002/path.4022)

Mohammed, Z.M.A., McMillan, D.C. , Elsberger, B., Going, J.J., Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 106(2), pp. 383-388. (doi: 10.1038/bjc.2011.569)

Spears, M., Taylor, K.J., Munro, A.F., Cunningham, C.A., Mallon, E.A., Twelves, C.J., Cameron, D.A., Thomas, J. and Bartlett, J.M.S. (2012) In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment, 132(2), pp. 463-470. (doi: 10.1007/s10549-011-1606-z)

Bartlett, J. M. S. et al. (2011) Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 29(12), pp. 1531-1538. (doi: 10.1200/JCO.2010.30.3677)

Cuzick, J. et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. Journal of Clinical Oncology, 29(32), pp. 4273-4278. (doi: 10.1200/JCO.2010.31.2835)

Dowsett, M., Salter, J., Zabaglo, L., Mallon, E., Howell, A., Buzdar, A. U., Forbes, J., Pineda, S. and Cuzick, J. (2011) Predictive algorithms for adjuvant therapy: TransATAC. Steroids, 76(8), pp. 777-780. (doi: 10.1016/j.steroids.2011.02.032)

Tovey, S.M., Brown, S.B., Doughty, J.C., Mallon, E.A., Cooke, T.G. and Edwards, J. (2009) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. British Journal of Cancer, 100(5), pp. 680-683. (doi: 10.1038/sj.bjc.6604940)

Bartlett, J., Campbell, F. and Mallon, E. (2008) Determination of HER2 Amplification by In Situ Hybridization: When Should Chromosome 17 also be Determined? American Journal of Clinical Pathology, 130(6), pp. 920-926.

Bartlett, J. et al. (2008) In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement - In reply. Journal of Clinical Oncology, 26(10), pp. 1769-1771.

Dowsett, M. et al. (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. Journal of Clinical Oncology, 26(7), pp. 1059-1065.

Pestalozzi, B. et al. (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology, 26(18), pp. 3006-3014. (doi: 10.1200/JCO.2007.14.9336)

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. , Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi: 10.1158/1078-0432.CCR-05-0283)

Stein, T. et al. (2005) Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clinical Cancer Research, 11(19), pp. 6872-6879. (doi: 10.1158/1078-0432.CCR-05-0547)

Bartlett, J.M.S., Mallon, E. and Cooke, T. (2003) The clinical evaluation of HER-2 status: which test to use? Journal of Pathology, 199(4), pp. 411-417. (doi: 10.1002/path.1354)

Dowsett, M. et al. (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. Journal of Pathology, 199(4), pp. 418-423. (doi: 10.1002/path.1313)

McIlhenny, C., Doughty, J.C., George, W.D. and Mallon, E.A. (2002) Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. British Journal of Surgery, 89, pp. 84-85.

Thomson, C.S., Twelves, C.J., Mallon, E.A. and Leake, R.E. (2002) Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast, 11, pp. 419-429. (doi: 10.1054/brst.2002.0451)